liberty street partners, LLC

attn phillippe pierre
188 liberty st
newburgh, new york 12550

NYS Entity Status
ACTIVE

NYS Filing Date
JANUARY 10, 2014

NYS DOS ID#
4511735

County
ORANGE

Jurisdiction
NEW YORK

Registered Agent
REGISTERED AGENT REVOKED

, ,

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2014 - LIBERTY STREET PARTNERS, LLC









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Extreme Commuting
    By BRYAN MILLER - Friday Jul 21, 2017

    The number of people who commute two hours or more to work is expected to grow, especially now that it is easier to work occasionally from home.

    Source: NYT > Home Page
  • Auction.com Parent Ten-X Gets New Ownership
    Tuesday Oct 3, 2017

    Private-equity firm Thomas H. Lee Partners LP has closed its purchase of a controlling stake in Ten-X LLC in a deal that values the online real estate marketplace at $1.6 billion, according to people familiar with the matter.

    Source: The Wall Street Journal: Technology: What's News
  • Religious Liberty Lives
    Monday Jun 26, 2017

    A 7-2 Supreme Court rebukes a relic of anti-Catholic bigotry.

    Source: The Wall Street Journal: Opinion
  • Sixgill®, LLC Launches Sense 2.0
    By Business Wire - Thursday Oct 12, 2017

    Sixgill, LLC, the leader in sensor data services for governing IoE, today unveiled the next generation of its universal and highly scalable sensor data services platform, Sixgill Sense 2.0. Sense 2.0 provides vital capabilities...

    Source: VentureBeat
  • WD Navarre Holdings Files for Chapter 11 Protection
    Friday Sep 8, 2017

    WD Navarre Holdings LLC, the corporate parent of technology products distributor WYNIT Distribution LLC, filed for bankruptcy protection Friday.

    Source: The Wall Street Journal: Technology: What's News
  • Regeneron Touts Success in Big Asthma Drug Study, Plans FDA Filing
    By Ben Fidler - Monday Sep 11, 2017

    A new drug for patients who have a hard time controlling their asthma could be nearing an FDA review. Tarrytown, NY-based Regeneron Pharmaceuticals (NASDAQ: REGN) and partner Sanofi this morning are touting results this morning from a 1,902-patient Phase 3 study called Liberty Asthma Quest. In it, their injectable antibody drug dupilumab (Dupixent), already approved […]

    Source: Xconomy New York